TM
CORT icon

Torren Management’s Corcept Therapeutics CORT Stock Holding History

Torren Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48K Hold
17
– – ﹤0.01% 650
2026
Q1 		$685 Sell
17
-702
-98% -$26.2K ﹤0.01% 817
2025
Q4 		$25K Buy
+719
New +$56.5K 0.01% 521

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Torren Management's CORT Position: Q2 2026 in Review

Torren Management held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 17 shares worth $1.48K. The position accounts for ﹤0.01% of the portfolio, ranked #650.

Torren Management first reported a position in CORT in Q4 2025 and has held it in 3 quarters since. The position peaked at $25K in Q4 2025. 188 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Torren Management held 17 shares of Corcept Therapeutics worth $1.48K as of Q2 2026.
  • Torren Management left its Corcept Therapeutics share count unchanged in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #650 holding.
  • Torren Management first reported a position in Corcept Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Torren Management's Corcept Therapeutics position peaked at $25K in Q4 2025.
  • 188 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.